Amneal Pharmaceuticals (AMRX) Stock Overview
A global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
AMRX Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amneal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.11 |
| 52 Week High | US$19.26 |
| 52 Week Low | US$9.20 |
| Beta | 1.25 |
| 1 Month Change | 3.49% |
| 3 Month Change | 45.81% |
| 1 Year Change | 92.45% |
| 3 Year Change | 342.79% |
| 5 Year Change | 226.31% |
| Change since IPO | 20.65% |
Recent News & Updates
Narrative Update • Aug 15
AMRX: Biosimilar And Generic Launches Will Drive The Next Leg Higher
Analysts have raised their price target on Amneal Pharmaceuticals to $25 from $23, citing a strong Q2 beat, an improved outlook, and the view that upcoming biosimilar and generic launches, along with a broader portfolio, could support higher long term revenue and margin assumptions in current models. Analyst Commentary Recent research on Amneal Pharmaceuticals points to increasingly constructive sentiment, with multiple bullish analysts lifting price targets following the strong Q2 report and updated guidance.Analysis Article • Aug 07
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) just reported healthy earnings but the stock price didn't move much...
Narrative Update • Aug 01
AMRX: Crexont And Biosimilars Will Test Fairly Valued 2026 Outlook
Analysts have lifted their fair value estimate for Amneal Pharmaceuticals by $2.00 to $20.25, citing updated assumptions on revenue growth, profit margins, and future P/E that reflect recent price target increases related to Crexont, Women's Health, and biosimilar progress. Analyst Commentary Recent commentary on Amneal Pharmaceuticals focuses on how key growth drivers and execution on upcoming launches could influence valuation over the next few years.
New Narrative • Aug 01
Biosimilars And GLP-1 Expansion Will Expose Mounting Operational And Execution Risks
Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals develops, manufactures and markets affordable medicines across generics, biosimilars and specialty products in the United States and selected global markets. What are the underlying business or industry changes driving this perspective?Recent updates
Narrative Update • Aug 15
AMRX: Biosimilar And Generic Launches Will Drive The Next Leg Higher
Analysts have raised their price target on Amneal Pharmaceuticals to $25 from $23, citing a strong Q2 beat, an improved outlook, and the view that upcoming biosimilar and generic launches, along with a broader portfolio, could support higher long term revenue and margin assumptions in current models. Analyst Commentary Recent research on Amneal Pharmaceuticals points to increasingly constructive sentiment, with multiple bullish analysts lifting price targets following the strong Q2 report and updated guidance.Analysis Article • Aug 07
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) just reported healthy earnings but the stock price didn't move much...Narrative Update • Aug 01
AMRX: Crexont And Biosimilars Will Test Fairly Valued 2026 Outlook
Analysts have lifted their fair value estimate for Amneal Pharmaceuticals by $2.00 to $20.25, citing updated assumptions on revenue growth, profit margins, and future P/E that reflect recent price target increases related to Crexont, Women's Health, and biosimilar progress. Analyst Commentary Recent commentary on Amneal Pharmaceuticals focuses on how key growth drivers and execution on upcoming launches could influence valuation over the next few years.New Narrative • Aug 01
Biosimilars And GLP-1 Expansion Will Expose Mounting Operational And Execution Risks
Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals develops, manufactures and markets affordable medicines across generics, biosimilars and specialty products in the United States and selected global markets. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jul 20
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism
Summary Amneal Pharmaceuticals has diversified beyond generics, driving margin expansion and improved financial health, but now trades near all-time highs. AMRX’s growth hinges on the Kashiv BioSciences acquisition, which is expected to add biosimilars and support management’s $4.25 billion 2030 revenue target. Despite improved operating leverage and reaffirmed 2026 guidance, persistent debt, settlement costs, and dilution from acquisitions cap free cash flow potential. My DCF analysis suggests AMRX is fully valued for management’s bullish projections; I maintain a neutral/Hold rating given limited upside and execution risks. Read the full article on Seeking AlphaNew Narrative • Jul 17
Biosimilars Expansion And Vertical Integration Will Reshape Long-Term Outlook
Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals focuses on affordable medicines across generics, specialty drugs and biosimilars, with a growing presence in large molecule therapies. What are the underlying business or industry changes driving this perspective?Narrative Update • Jul 15
AMRX: Biosimilars And 2026 Execution Will Shape Fairly Valued Outlook
Analysts have raised their fair value estimate for Amneal Pharmaceuticals by $1 to $18.25, citing higher price targets from recent research, confidence in growth from Crexont, Women's Health and biosimilars, and support from improving expectations reflected in a modestly higher assumed future P/E multiple. Analyst Commentary Recent Street research on Amneal Pharmaceuticals highlights a mix of enthusiasm around growth drivers like Crexont, Women's Health and biosimilars, alongside a few areas where execution and valuation expectations could face tests.Analysis Article • Jun 21
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
Why Amneal Pharmaceuticals Stock Is On Investors’ Radar Amneal Pharmaceuticals (AMRX) has been drawing attention after a strong share price move over the past month and past 3 months, prompting investors to reassess what the current valuation implies. The stock recently closed at US$16.21, and available data shows it trades at a discount to one independent intrinsic value estimate. This may interest readers comparing Amneal to other US biopharmaceutical companies. See our latest analysis for...Narrative Update • Jun 19
AMRX: Biosimilar Buildout And 2026 Execution Will Shape Fairly Valued Stock
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals up to $17.25 from $17.20, citing higher projected profit margins and renewed confidence in the 2026 outlook as the company works to narrow its valuation gap with peers and advance its biosimilar efforts. Analyst Commentary Recent research on Amneal Pharmaceuticals highlights a mix of optimism on the 2026 setup and some areas where investors may want to stay disciplined on execution and valuation.Narrative Update • Jun 04
AMRX: Biosimilar Execution And 2026 Outlook Will Support Share Rebound
Analysts have inched their fair value estimate for Amneal Pharmaceuticals up from $17.00 to $17.20 and raised the price target to $16.00, citing stronger confidence in the fiscal 2026 outlook, a solid Q1 update, and an increasing focus on biosimilar opportunities compared with peers. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Q1 report as a key support for their higher fair value estimates, viewing the current execution as consistent with their fiscal 2026 expectations.Narrative Update • May 04
AMRX: 2026 EBITDA Outlook Will Support Rebound After GRx Driven Pullback
Amneal Pharmaceuticals' consensus analyst price target has shifted to $17.00, with analysts citing solid Q4 results, strengthened FY26 EBITDA guidance and a reset future P/E assumption as support for this updated view. Analyst Commentary Recent research has focused on how Amneal Pharmaceuticals' updated FY26 guidance and Q4 performance feed into valuation, growth expectations and execution risk around that new US$17.00 price target.Narrative Update • Apr 19
AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup
Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.Narrative Update • Apr 02
AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup
Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.Narrative Update • Mar 18
AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback
Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.Narrative Update • Mar 04
AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup
Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.Narrative Update • Feb 17
AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup
Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.Narrative Update • Feb 03
AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook
Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.Narrative Update • Jan 19
AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook
Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.Narrative Update • Jan 05
AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.Narrative Update • Dec 13
AMRX: Complex Generics Approvals Will Support Future Earnings Upside
Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.Analysis Article • Nov 30
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Despite an already strong run, Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shares have been powering on, with a gain...Narrative Update • Nov 29
AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook
Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.Narrative Update • Nov 15
AMRX: Sustained Outperformance Will Drive Future Earnings Confidence
Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.Analysis Article • Nov 14
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) recently posted some strong earnings, and the market responded positively...Narrative Update • Nov 01
AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum
Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.Narrative Update • Sep 17
Global Health Trends And Pipeline Launches Will Fuel Future Potential
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.
New Narrative • Mar 22
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.Shareholder Returns
| AMRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.5% | 2.3% | -0.3% |
| 1Y | 92.5% | 53.6% | 19.9% |
Return vs Industry: AMRX exceeded the US Pharmaceuticals industry which returned 53.6% over the past year.
Return vs Market: AMRX exceeded the US Market which returned 19.9% over the past year.
Price Volatility
| AMRX volatility | |
|---|---|
| AMRX Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMRX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 8,700 | Chirag Patel | www.amneal.com |
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
Amneal Pharmaceuticals, Inc. Fundamentals Summary
| AMRX fundamental statistics | |
|---|---|
| Market cap | US$5.81b |
| Earnings (TTM) | US$157.36m |
| Revenue (TTM) | US$3.12b |
36.8x
P/E Ratio1.9x
P/S RatioIs AMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRX income statement (TTM) | |
|---|---|
| Revenue | US$3.12b |
| Cost of Revenue | US$1.88b |
| Gross Profit | US$1.24b |
| Other Expenses | US$1.08b |
| Earnings | US$157.36m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 39.81% |
| Net Profit Margin | 5.05% |
| Debt/Equity Ratio | 2,282.7% |
How did AMRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/19 23:17 |
| End of Day Share Price | 2026/08/19 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| David Buck | B. Riley Securities, Inc. |